Taurolidine and Heparin
Brand Names: Defencath
Methodology & AI Transparency ⓘ
Taurolidine and Heparin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Taurolidine and Heparin (40.5 mg/3mL / 3000 [USP'U]/3mL Solution; NDC 72990-103) as a intraluminal-route anti-coagulant formulation manufactured/labeled by CorMedix Inc.
- 2 Real-world patient consensus: 78% patient "Worth It" rating across 6 anonymous logs for Taurolidine and Heparin (RxNorm RXN-72990103-3142).
- 3 Typical cash cost range: 30-day cash pricing ranges from $150.25 discount cash to $368.11 walk-in retail (NADAC $3.5000/unit).
- 4 Top reported side effects / signs: Most commonly reported Taurolidine and Heparin tolerability events: nausea (8.9%), headache (8.4%), dizziness (6.8%).
Ask our AI Specialists anything about Taurolidine and Heparin
Taurolidine and Heparin Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Taurolidine and Heparin (40.5 mg/3mL / 3000 [USP'U]/3mL Solution; NDC 72990-103) as a intraluminal-route anti-coagulant formulation manufactured/labeled by CorMedix Inc. when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Taurolidine and Heparin exerts selective anti-coagulant pharmacodynamic activity across 40.5 mg/3mL / 3000 [USP'U]/3mL Solution (intraluminal-route route, manufactured/labeled by CorMedix Inc.), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 72990-103).
Pharmacokinetic profiling of Taurolidine and Heparin demonstrates an elimination half-life of Terminal t½ estimated at 7–19 hrs depending on renal/hepatic reserve (Taurolidine and Heparin) with F ≈ 77%–89% systemic availability after standard oral Taurolidine and Heparin administration systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across taurolidine and heparin regimens, reaching clinical onset within time to peak concentration spans 1 to 2 hrs under taurolidine and heparin maintenance.
Titration schedules for Taurolidine and Heparin (40.5 mg/3mL / 3000 [USP'U]/3mL Solution → 40.5 mg/3mL → 3mL) require excluding known hypersensitivity to taurolidine and heparin or structurally related anti-coagulant compounds; concomitant contra-labeled cyp/transporter therapies during active taurolidine and heparin administration; real-world patient logs highlight nausea (8.9% of reports), headache (8.4% of reports), dizziness (6.8% of reports) alongside a 78.00% Worth-It consensus.
Avoid overlapping anti-coagulant prescriptions alongside Taurolidine and Heparin to prevent cumulative receptor toxicity.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Taurolidine and Heparin dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Taurolidine and Heparin or structurally related anti-coagulant compounds
- Concomitant contra-labeled CYP/transporter therapies during active Taurolidine and Heparin administration
Logged Side-Effect Incidence (6 Reports)
Taurolidine and Heparin Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Taurolidine and Heparin)
Human clinical trial evidence for Taurolidine and Heparin is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Taurolidine and Heparin Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.5000/unit (~$105.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $368.11 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $150.25 / mo | View logs ↓ |
Taurolidine and Heparin Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Taurolidine and Heparin RxNorm Concept ID | RXN-72990103-3142 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.5000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $368.11 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $150.25 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 78.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Taurolidine and Heparin Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Taurolidine and Heparin integrating DailyMed SPL (2026-07-01), CMS NADAC ($3.5000/unit), and 6 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Taurolidine and Heparin community threads and patient logs by age, biological sex, dosage, and treatment duration.